Does the media favor ROIV or MIRM?

In the previous week, Mirum Pharmaceuticals had 18 more articles in the media than Roivant Sciences. MarketBeat recorded 35 mentions for Mirum Pharmaceuticals and 17 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 0.97 beat Mirum Pharmaceuticals' score of 0.11 indicating that Roivant Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 8 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mirum Pharmaceuticals 6 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media favor MIRM or BNTX?

In the previous week, Mirum Pharmaceuticals had 11 more articles in the media than BioNTech. MarketBeat recorded 35 mentions for Mirum Pharmaceuticals and 24 mentions for BioNTech. Mirum Pharmaceuticals' average media sentiment score of 0.11 beat BioNTech's score of -0.11 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 6 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral BioNTech 4 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 8 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor MIRM or INSM?

In the previous week, Mirum Pharmaceuticals had 12 more articles in the media than Insmed. MarketBeat recorded 35 mentions for Mirum Pharmaceuticals and 23 mentions for Insmed. Insmed's average media sentiment score of 0.70 beat Mirum Pharmaceuticals' score of 0.11 indicating that Insmed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 6 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral Insmed 8 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to MIRM or MRNA?

In the previous week, Moderna had 22 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 57 mentions for Moderna and 35 mentions for Mirum Pharmaceuticals. Moderna's average media sentiment score of 0.49 beat Mirum Pharmaceuticals' score of 0.11 indicating that Moderna is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 6 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral Moderna 21 Very Positive mention(s) 8 Positive mention(s) 16 Neutral mention(s) 7 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor MIRM or VTRS?

In the previous week, Mirum Pharmaceuticals had 22 more articles in the media than Viatris. MarketBeat recorded 35 mentions for Mirum Pharmaceuticals and 13 mentions for Viatris. Viatris' average media sentiment score of 0.46 beat Mirum Pharmaceuticals' score of 0.11 indicating that Viatris is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 6 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral Viatris 0 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Mirum Pharmaceuticals (MIRM) Competitors

$97.93 -2.72 (-2.71%)

As of 10:49 AM Eastern

Compare

MIRM vs. ROIV, BNTX, INSM, MRNA, and VTRS

Should you buy Mirum Pharmaceuticals stock or one of its competitors? MarketBeat compares Mirum Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Mirum Pharmaceuticals include Roivant Sciences (ROIV), BioNTech (BNTX), Insmed (INSM), Moderna (MRNA), and Viatris (VTRS).

How does Mirum Pharmaceuticals compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability and risk.

Roivant Sciences has a beta of 1.12, indicating that its stock price is 12% more volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.52, indicating that its stock price is 48% less volatile than the broader market.

64.8% of Roivant Sciences shares are held by institutional investors. 8.8% of Roivant Sciences shares are held by company insiders. Comparatively, 8.3% of Mirum Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Mirum Pharmaceuticals had 18 more articles in the media than Roivant Sciences. MarketBeat recorded 35 mentions for Mirum Pharmaceuticals and 17 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 0.97 beat Mirum Pharmaceuticals' score of 0.11 indicating that Roivant Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	8 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mirum Pharmaceuticals	6 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral

Mirum Pharmaceuticals has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$7.53M	3,477.36	-$299.77M	-$0.53	N/A
Mirum Pharmaceuticals	$521.31M	12.20	-$23.36M	-$14.55	N/A

Roivant Sciences presently has a consensus target price of $34.77, indicating a potential downside of 4.51%. Mirum Pharmaceuticals has a consensus target price of $137.33, indicating a potential upside of 40.24%. Given Mirum Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Mirum Pharmaceuticals is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

Mirum Pharmaceuticals has a net margin of -139.18% compared to Roivant Sciences' net margin of -3,534.96%. Roivant Sciences' return on equity of -22.94% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,534.96%	-22.94%	-21.53%
Mirum Pharmaceuticals	-139.18%	-36.28%	-8.54%

Summary

Mirum Pharmaceuticals beats Roivant Sciences on 9 of the 16 factors compared between the two stocks.

How does Mirum Pharmaceuticals compare to BioNTech?

Mirum Pharmaceuticals (NASDAQ:MIRM) and BioNTech (NASDAQ:BNTX) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

Mirum Pharmaceuticals has a beta of 0.52, indicating that its stock price is 48% less volatile than the broader market. Comparatively, BioNTech has a beta of 1.27, indicating that its stock price is 27% more volatile than the broader market.

In the previous week, Mirum Pharmaceuticals had 11 more articles in the media than BioNTech. MarketBeat recorded 35 mentions for Mirum Pharmaceuticals and 24 mentions for BioNTech. Mirum Pharmaceuticals' average media sentiment score of 0.11 beat BioNTech's score of -0.11 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	6 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral
BioNTech	4 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	8 Negative mention(s)	0 Very Negative mention(s)	Neutral

Mirum Pharmaceuticals currently has a consensus target price of $137.33, suggesting a potential upside of 40.24%. BioNTech has a consensus target price of $127.81, suggesting a potential upside of 36.22%. Given Mirum Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Mirum Pharmaceuticals is more favorable than BioNTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74

Mirum Pharmaceuticals has higher earnings, but lower revenue than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	12.20	-$23.36M	-$14.55	N/A
BioNTech	$3.25B	7.31	-$1.29B	-$7.83	N/A

BioNTech has a net margin of -63.54% compared to Mirum Pharmaceuticals' net margin of -139.18%. BioNTech's return on equity of -6.86% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-139.18%	-36.28%	-8.54%
BioNTech	-63.54%	-6.86%	-6.00%

15.5% of BioNTech shares are owned by institutional investors. 8.3% of Mirum Pharmaceuticals shares are owned by insiders. Comparatively, 19.2% of BioNTech shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

BioNTech beats Mirum Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Mirum Pharmaceuticals compare to Insmed?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Insmed (NASDAQ:INSM) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations, media sentiment and valuation.

Mirum Pharmaceuticals presently has a consensus target price of $137.33, indicating a potential upside of 40.24%. Insmed has a consensus target price of $205.26, indicating a potential upside of 54.96%. Given Insmed's stronger consensus rating and higher possible upside, analysts plainly believe Insmed is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	2 Strong Buy rating(s)	3.00

Mirum Pharmaceuticals has a beta of 0.52, meaning that its share price is 48% less volatile than the broader market. Comparatively, Insmed has a beta of 0.81, meaning that its share price is 19% less volatile than the broader market.

Insmed has a net margin of -76.94% compared to Mirum Pharmaceuticals' net margin of -139.18%. Mirum Pharmaceuticals' return on equity of -36.28% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-139.18%	-36.28%	-8.54%
Insmed	-76.94%	-123.94%	-44.30%

Mirum Pharmaceuticals has higher earnings, but lower revenue than Insmed. Insmed is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	12.20	-$23.36M	-$14.55	N/A
Insmed	$1.14B	25.24	-$1.28B	-$4.11	N/A

In the previous week, Mirum Pharmaceuticals had 12 more articles in the media than Insmed. MarketBeat recorded 35 mentions for Mirum Pharmaceuticals and 23 mentions for Insmed. Insmed's average media sentiment score of 0.70 beat Mirum Pharmaceuticals' score of 0.11 indicating that Insmed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	6 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral
Insmed	8 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Insmed beats Mirum Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Mirum Pharmaceuticals compare to Moderna?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Moderna (NASDAQ:MRNA) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, institutional ownership, analyst recommendations and risk.

Mirum Pharmaceuticals has a beta of 0.52, indicating that its share price is 48% less volatile than the broader market. Comparatively, Moderna has a beta of 0.91, indicating that its share price is 9% less volatile than the broader market.

Mirum Pharmaceuticals has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	12.20	-$23.36M	-$14.55	N/A
Moderna	$1.94B	12.29	-$2.82B	-$7.99	N/A

In the previous week, Moderna had 22 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 57 mentions for Moderna and 35 mentions for Mirum Pharmaceuticals. Moderna's average media sentiment score of 0.49 beat Mirum Pharmaceuticals' score of 0.11 indicating that Moderna is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	6 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral
Moderna	21 Very Positive mention(s)	8 Positive mention(s)	16 Neutral mention(s)	7 Negative mention(s)	0 Very Negative mention(s)	Neutral

Mirum Pharmaceuticals presently has a consensus target price of $137.33, suggesting a potential upside of 40.24%. Moderna has a consensus target price of $42.13, suggesting a potential downside of 29.62%. Given Mirum Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Mirum Pharmaceuticals is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Moderna	5 Sell rating(s)	9 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	1.88

75.3% of Moderna shares are held by institutional investors. 8.3% of Mirum Pharmaceuticals shares are held by insiders. Comparatively, 10.8% of Moderna shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Mirum Pharmaceuticals has a net margin of -139.18% compared to Moderna's net margin of -141.43%. Moderna's return on equity of -28.30% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-139.18%	-36.28%	-8.54%
Moderna	-141.43%	-28.30%	-19.39%

Summary

Moderna beats Mirum Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Mirum Pharmaceuticals compare to Viatris?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Viatris (NASDAQ:VTRS) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk, media sentiment and valuation.

Mirum Pharmaceuticals has a beta of 0.52, suggesting that its stock price is 48% less volatile than the broader market. Comparatively, Viatris has a beta of 0.9, suggesting that its stock price is 10% less volatile than the broader market.

Viatris has a net margin of -2.79% compared to Mirum Pharmaceuticals' net margin of -139.18%. Viatris' return on equity of 20.02% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-139.18%	-36.28%	-8.54%
Viatris	-2.79%	20.02%	8.02%

79.9% of Viatris shares are owned by institutional investors. 8.3% of Mirum Pharmaceuticals shares are owned by company insiders. Comparatively, 0.3% of Viatris shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Mirum Pharmaceuticals currently has a consensus price target of $137.33, indicating a potential upside of 40.24%. Viatris has a consensus price target of $17.50, indicating a potential upside of 7.73%. Given Mirum Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Mirum Pharmaceuticals is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Viatris	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

Mirum Pharmaceuticals has higher earnings, but lower revenue than Viatris. Viatris is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	12.20	-$23.36M	-$14.55	N/A
Viatris	$14.30B	1.32	-$3.51B	-$0.36	N/A

In the previous week, Mirum Pharmaceuticals had 22 more articles in the media than Viatris. MarketBeat recorded 35 mentions for Mirum Pharmaceuticals and 13 mentions for Viatris. Viatris' average media sentiment score of 0.46 beat Mirum Pharmaceuticals' score of 0.11 indicating that Viatris is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	6 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral
Viatris	0 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Mirum Pharmaceuticals beats Viatris on 9 of the 17 factors compared between the two stocks.

Get Mirum Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MIRM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MIRM vs. The Competition

Export

Metric	Mirum Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.38B	$3.71B	$7.02B	$12.96B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-6.75	9.07	269.90	24.97
Price / Sales	12.20	1,294.66	659.13	107.89
Price / Cash	1,974.34	44.95	28.89	37.44
Price / Book	16.00	17.71	11.29	6.44
Net Income	-$23.36M	-$13.25M	$3.45B	$347.50M
7 Day Performance	-6.37%	5.42%	3.56%	3.82%
1 Month Performance	-19.82%	-1.71%	-0.57%	-0.37%
1 Year Performance	63.29%	61.70%	77.67%	23.81%

Mirum Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MIRM Mirum Pharmaceuticals	2.9712 of 5 stars	$97.93 -2.7%	$137.33 +40.2%	+67.8%	$6.38B	$521.31M	N/A	140	Positive News Earnings Report Analyst Upgrade Analyst Revision
ROIV Roivant Sciences	1.5127 of 5 stars	$32.87 -2.9%	$33.59 +2.2%	+216.3%	$24.34B	$8.26M	N/A	860	Analyst Forecast
BNTX BioNTech	3.871 of 5 stars	$92.95 +0.5%	$129.13 +38.9%	-16.1%	$23.38B	$3.25B	N/A	7,807	Analyst Downgrade
INSM Insmed	3.8251 of 5 stars	$103.12 -1.0%	$209.35 +103.0%	+19.7%	$22.57B	$606.42M	N/A	1,664	Earnings Report Analyst Forecast
MRNA Moderna	1.3644 of 5 stars	$54.49 -2.4%	$40.00 -26.6%	+126.5%	$22.14B	$1.94B	N/A	4,700	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MIRM) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mirum Pharmaceuticals (MIRM) Competitors

MIRM vs. ROIV, BNTX, INSM, MRNA, and VTRS

How does Mirum Pharmaceuticals compare to Roivant Sciences?

Summary

How does Mirum Pharmaceuticals compare to BioNTech?

Summary

How does Mirum Pharmaceuticals compare to Insmed?

Summary

How does Mirum Pharmaceuticals compare to Moderna?

Summary

How does Mirum Pharmaceuticals compare to Viatris?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MIRM vs. The Competition

Mirum Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mirum Pharmaceuticals (MIRM) Competitors

MIRM vs. ROIV, BNTX, INSM, MRNA, and VTRS

How does Mirum Pharmaceuticals compare to Roivant Sciences?

Which has more volatility and risk, ROIV or MIRM?

Do insiders and institutionals believe in ROIV or MIRM?

Does the media favor ROIV or MIRM?

Which has preferable earnings & valuation, ROIV or MIRM?

Do analysts prefer ROIV or MIRM?

Is ROIV or MIRM more profitable?

Summary

How does Mirum Pharmaceuticals compare to BioNTech?

Which has more volatility and risk, MIRM or BNTX?

Does the media favor MIRM or BNTX?

Do analysts prefer MIRM or BNTX?

Which has preferable earnings and valuation, MIRM or BNTX?

Is MIRM or BNTX more profitable?

Do institutionals & insiders have more ownership in MIRM or BNTX?

Summary

How does Mirum Pharmaceuticals compare to Insmed?

Do analysts recommend MIRM or INSM?

Which has more volatility and risk, MIRM or INSM?

Is MIRM or INSM more profitable?

Which has higher earnings & valuation, MIRM or INSM?

Does the media favor MIRM or INSM?

Summary

How does Mirum Pharmaceuticals compare to Moderna?

Which has more risk & volatility, MIRM or MRNA?

Which has higher valuation and earnings, MIRM or MRNA?

Does the media refer more to MIRM or MRNA?

Do analysts recommend MIRM or MRNA?

Do insiders and institutionals hold more shares of MIRM or MRNA?

Is MIRM or MRNA more profitable?

Summary

How does Mirum Pharmaceuticals compare to Viatris?

Which has more volatility and risk, MIRM or VTRS?

Is MIRM or VTRS more profitable?

Do institutionals & insiders believe in MIRM or VTRS?

Do analysts rate MIRM or VTRS?

Which has higher valuation and earnings, MIRM or VTRS?

Does the media favor MIRM or VTRS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MIRM vs. The Competition

Mirum Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools